B+
Bull case
20%
Probability
Target price
$0.38
Analysis reference price unavailable
Analysis 2026-10-20 · RankAlpha Sentiment Codex
GOVX
GeoVax LabsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$0.19
Analysis reference price unavailable
Analysis 2026-10-20 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$0.06
Analysis reference price unavailable
Analysis 2026-10-20 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-20
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+56.0
Score
AI commentary
Recent company-led coverage emphasizes study preparation, while the confirmed proxy and financing disclosures keep the risk balance negative. No reliable post-hearing outcome, attributable price reaction, analyst revision, or sufficient social, options, short-interest, or employee-sentiment measure was established. Zero-valued sentiment fields denote unavailable data, not neutral readings.
RankAlpha Sentiment Codex - 2026-10-20
Open full AI memoEvidence flagged
small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-27eventOctober 27 shareholder voteHigh impact
Shareholders are scheduled to vote on a discretionary 1-for-10 to 1-for-25 reverse split and issuance of up to 11,395,256 shares upon warrant exercise. Approval could aid Nasdaq compliance and potential funding, but exercise is not assured and would dilute holders. [#SEC-DEF14A-2026-09-10] https://www.sec.gov/Archives/edgar/data/832489/000143774926030089/govx20260904_def14a.htm
2026-11-30catalystNasdaq listing decision remains unresolvedHigh impact
GeoVax said its appeal stayed delisting pending an October 13 hearing and any extension. No subsequent panel outcome was confirmed in the checked sources; continued listing must not be assumed. [#8-K-2026-09-10] https://www.sec.gov/Archives/edgar/data/832489/000143774926030085/ex_1014466.htm
2026-12-31eventGEO-MVA pivotal-study initiationHigh impact
Management targeted fourth-quarter initiation of its GEO-MVA immunobridging study. A September agreement gives GeoVax access to CEPI-network sample testing, supporting preparation but not establishing trial initiation, clinical success, or CEPI funding. [#SEC-8K-2026-07-27] [#PR-2026-09-14] https://www.sec.gov/Archives/edgar/data/832489/000143774926024522/ex_993355.htm https://geovax.com/geovax-and-cepi-enter-agreement-to-utilize-cepi-centralised-laboratory-network-to-support-geo-mva-phase-3-trial/
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-20 • Updated nightlySource: Internal modelMethodology